397 related articles for article (PubMed ID: 25645201)
1. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
[TBL] [Abstract][Full Text] [Related]
5. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
7. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
9. Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses.
Mori M; An Y; Katayama O; Kitagawa T; Sasaki Y; Onaka T; Yonezawa A; Murata K; Yokota T; Ando K; Imada K
Ann Hematol; 2015 Nov; 94(11):1885-90. PubMed ID: 26251157
[TBL] [Abstract][Full Text] [Related]
10. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?
Suhr OB; Anan I; Backman C; Karlsson A; Lindqvist P; Mörner S; Waldenström A
J Intern Med; 2008 Mar; 263(3):294-301. PubMed ID: 18069997
[TBL] [Abstract][Full Text] [Related]
11. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
12. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
13. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
14. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
Ternacle J; Bodez D; Guellich A; Audureau E; Rappeneau S; Lim P; Radu C; Guendouz S; Couetil JP; Benhaiem N; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Mohty D; Deux JF; Damy T
JACC Cardiovasc Imaging; 2016 Feb; 9(2):126-38. PubMed ID: 26777222
[TBL] [Abstract][Full Text] [Related]
15. Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis.
Cappelli F; Baldasseroni S; Bergesio F; Padeletti L; Attanà P; Pignone AM; Grifoni E; Ciuti G; Fabbri A; Tarantini F; Marchionni N; Gensini GF; Perfetto F
Amyloid; 2014 Jun; 21(2):97-102. PubMed ID: 24517408
[TBL] [Abstract][Full Text] [Related]
16. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis.
Bodez D; Guellich A; Kharoubi M; Covali-Noroc A; Tissot CM; Guendouz S; Hittinger L; Dubois-Randé JL; Lefaucheur JP; Planté-Bordeneuve V; Adnot S; Boyer L; Damy T
Sleep; 2016 Jul; 39(7):1333-41. PubMed ID: 27091529
[TBL] [Abstract][Full Text] [Related]
18. The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction.
Yalvaç HE; Murat S; Ak Sivrikoz İ; Üsküdar Teke H; Çilingir O; Çolak E; Çavuşoğlu Y
Turk Kardiyol Dern Ars; 2024 Jun; 52(4):227-236. PubMed ID: 38829635
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
[TBL] [Abstract][Full Text] [Related]
20. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.
Klaassen SHC; Tromp J; Nienhuis HLA; van der Meer P; van den Berg MP; Blokzijl H; van Veldhuisen DJ; Hazenberg BPC
Am J Cardiol; 2018 Jan; 121(1):107-112. PubMed ID: 29153245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
